Harbor Capital Advisors, Inc. Tcr2 Therapeutics Inc. Transaction History

Harbor Capital Advisors, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 26, 2023	SELL	$1.0 - $1.62 $588 - $952	-588 Reduced 0.86%	67,642 $101,000
Q4 2022 Jan 20, 2023	SELL	$0.83 - $1.44 $1,205 - $2,092	-1,453 Reduced 2.09%	68,230 $0
Q3 2022 Oct 28, 2022	BUY	$1.86 - $3.75 $9,936 - $20,032	5,342 Added 8.3%	69,683 $125,000
Q2 2022 Jul 26, 2022	SELL	$2.11 - $2.94 $6,798 - $9,472	-3,222 Reduced 4.77%	64,341 $187,000
Q1 2022 Apr 28, 2022	SELL	$2.4 - $4.71 $38,534 - $75,623	-16,056 Reduced 19.2%	67,563 $186,000
Q4 2021 Feb 04, 2022	BUY	$4.58 - $8.34 $382,975 - $697,382	83,619 New	83,619 $390,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.